DPP-4 inhibitors are no more efficient in lowering blood glucose concentrations and reducing HbA1c levels than the older molecules and they provide certain advantages such as an insignificant risk of hypoglycemia and a weight-neutral profile. This evidence concerns the gene DPP4 and Hypoglycemia.